Patent Assignment
Reel/Frame 021266/0729
Merger
Recorded: 2008-07-21
Received: 2008-07-21
Pages: 18
Assignor
ALCON MANUFACTURING, LTD.
Executed: 2008-01-01
Assignee
ALCON RESEARCH, LTD.
6201 SOUTH FREEWAY, IP LEGAL, TB4-8, FORT WORTH, TX, 76134-2099, UNITED STATES
Covered Properties
(100)
Glass Drug Chamber For Automated Ophthalmic Injection Device
Application:
11/971,443 →
Inhibitors of Protein Kinase C-Delta for the Treatment of Glaucoma
Application:
11/961,493 →
Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone
Application:
11/960,196 →
Phase Transition Pharmaceutical Mold For Producing Pellets For Injection Device
Application:
11/954,890 →
Vacuum Drug Pellet Molding
Application:
11/955,035 →
Charging Base with Testing Capability for Medical Device
Application:
11/953,580 →
Use of Peo-Pbo Block Copolymers in Ophthalmic Compositions
Application:
11/953,654 →
Substantially Pure Fluorescein
Application:
11/949,922 →
Use of Connective Tissue Mast Cell Stabilizers to Facilitate Ocular Surface Re-Epithelization and Wound Repair
Application:
11/947,041 →
RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS
Application:
11/946,335 →
RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
Application:
11/946,395 →
Fan-Shaped Cannula For Sealing Ophthalmic Incisions
Application:
11/939,005 →
Water Insoluble Polymer Matrix for Drug Delivery
Application:
11/936,914 →
Punctal Plug Comprising a Water-Insoluble Polymeric Matrix
Application:
11/936,875 →
Devices and Methods for Ophthalmic Drug Delivery
Application:
11/936,842 →
Method of Treating Asthma, Allergic Rhinitis, and Skin Disorders
Application:
11/935,457 →
Lens Delivery System
Application:
11/928,554 →
2-Pyrrolidone Derivatives for Preservation of Ophthalmic, Otic and Nasal Compositions
Application:
11/877,979 →
Packaging Materials for Formulations Containing 2-Pyrrolidone Derivatives
Application:
11/923,032 →
Intraocular Lenses with Unique Blue-Violet Cutoff and Blue Light Transmission Characteristics
Application:
11/871,411 →
Intraocular Lens
Application:
11/862,244 →
Self Preserved Aqueous Pharmaceutical Compositions
Application:
11/858,781 →
Rnai-Mediated Inhibition of Gremlin for Treatment of Iop-Related Conditions
Application:
11/844,869 →
Plunger Linkage Method For Ophthalmic Medical Device
Application:
11/833,518 →
Drug Casting
Application:
11/833,668 →
Consumable Activation Lever For Injection Device
Application:
11/833,369 →
Easy Cleaning C-Shaped Charging Base
Application:
11/833,384 →
Plunger Linkage and Seal For Ophthalmic Medical Device
Application:
11/833,471 →
Process for Preparing Pyranoindazole Serotonergic Receptor Agonists
Application:
11/832,531 →
Ophthalmic Injection Method
Application:
11/832,333 →
Limited Reuse Assembly For Ophthalmic Injection Device
Application:
11/832,364 →
Intermediates and Methods for Serotonergic Agonist Synthesis
Application:
11/832,572 →
Disposable Ophthalmic Injection Device
Application:
11/832,243 →
Ophthalmic Injection System
Application:
11/832,301 →
Retractable Injection Port
Application:
11/781,719 →
Arced Hypodermic Needle
Application:
11/781,646 →
Low-Tack Ophthalmic and Otorhinolaryngological Device Materials
Application:
11/780,635 →
Low-Tack Ophthalmic and Otorhinolaryngological Device Materials
Application:
11/780,649 →
Dual Thermal Coefficient Dispensing Chamber
Application:
11/777,408 →
Foot Controller With Force Sensor For Proportional Control
Application:
11/768,568 →
Temperature Release Mechanism for Injection Device
Application:
11/762,844 →
Aryl and Heteroaryl Tetrahydrobenzazepine Derivatives and Their Use for Treating Glaucoma
Application:
11/761,493 →
Ophthalmic Injection Device Using Shape Memory Alloy
Application:
11/752,064 →
Mechanical Linkage Mechanism For Ophthalmic Injection Device
Application:
11/752,011 →
Ophthalmic Injection Device Using Piezoelectric Array
Application:
11/751,981 →
Ophthalmic Injection System and Method Using Piezoelectric Array
Application:
11/751,934 →
Rnai-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
Application:
11/750,262 →
Intraocular Lens with Edge Modification
Application:
11/742,202 →
Prenyltransferase Inhibitors for Ocular Hypertension Control and the Treatment of Glaucoma
Application:
11/692,316 →
Dosage Control Device
Application:
11/688,573 →
Fuse Assembly For Single Use Medical Device
Application:
11/688,489 →
Lens Delivery System Cartridge
Application:
11/684,337 →
Lens Delivery System
Application:
11/682,622 →
Superoxide Dismutase-2 Expression for Glaucoma Diagnosis
Application:
11/680,416 →
Use of Natriuretic Peptide Receptor Antagonists to Treat Ocular, Otic and Nasal Edemetous Conditions
Application:
11/679,991 →
Method of Treating Glaucoma
Application:
11/679,629 →
Method of Treating Dry Eye Disorders
Application:
11/678,655 →
Lens Delivery System
Application:
11/675,402 →
Lens Delivery System
Application:
11/675,380 →
Intraocular Lens
Application:
11/619,045 →
RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
11/617,899 →
C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
Application:
11/614,595 →
Composition and Methods for Inhibiting the Progression Macular Degeneration and Promoting Healthy Vision
Application:
11/613,938 →
RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
Application:
11/641,410 →
Hydroxyamino- and Amino-Substituted Pyridine Analogs for Treating Rho Kinase-Mediated Diseases and Conditions
Application:
11/612,932 →
(Indazol-5-Yl)-Pyrazines and (1,3-Dihydro-Indol-2-One)-Pyrazines for Treating Glaucoma and Controlling Intraocular Pressure
Application:
11/612,894 →
Ophthalmic Compositions Containing Galactomannan Polymers and Borate
Application:
11/612,579 →
RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
Application:
11/642,016 →
Method of Treating Ocular Allergy
Application:
11/593,714 →
Intraocular lens delivery system with temperature control
Application:
11/584,996 →
Method of Delivering Temperature Controlled Intraocular Lens
Application:
11/584,997 →
Self-Preserved Aqueous Pharmaceutical Compositions
Application:
60/827,417 →
Spring actuated delivery system
Application:
11/527,858 →
Ophthalmic injection system
Application:
11/527,245 →
Ophthalmic injection method
Application:
11/527,244 →
Self-Preserved Aqueous Pharmaceutical Compositions
Application:
60/826,514 →
Truncated diffractive intraocular lenses
Application:
11/444,112 →
Safety battery meter system for surgical hand piece
Application:
11/504,910 →
Lens Delivery System
Application:
11/503,851 →
Battery charging safety system for surgical hand piece
Application:
11/498,400 →
Apodized Diffractive Iol with Frustrated Diffractive Region
Application:
11/497,594 →
Ophthalmic injector
Application:
11/486,870 →
RNAi-mediated inhibition of stromal cell-derived factor 1-related targets for treatment of neovascularization-related conditions
Application:
60/810,273 →
RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
Application:
60/801,788 →
Correction of Higher Order Aberrations in Intraocular Lenses
Application:
11/435,905 →
RNAi-mediated inhibition of histamine receptor H1-related conditions
Application:
60/791,623 →
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
Application:
60/791,847 →
Use of AP-1 activators to treat glaucoma and ocular hypertension
Application:
11/354,326 →
Pseudo-Accommodative Iol Having Diffractive Zones with Varying Areas
Application:
11/350,497 →
Pseudo-Accommodative Iol Having Multiple Diffractive Patterns
Application:
11/350,505 →
Intra-ocular device with multiple focusing powers/optics
Application:
11/350,437 →
Use of low molecular weight amino alcohols in ophthalmic compositions
Application:
11/343,068 →
Plunger
Application:
11/336,043 →
Serotonergic 5HT7 Receptor Compounds for Treating Ocular and Cns Disorders
Application:
11/265,030 →
Maintaining preoperative position of the posterior lens capsule after cataract surgery
Application:
11/254,945 →
Use of PDE IV inhibitors to treat angiogenesis
Application:
11/204,938 →
Use of Low Molecular Weight Amino Alcohols in Ophthalmic Compositions
Application:
11/168,788 →
Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
Application:
11/109,115 →
Serotonergic 5HT7 Receptor Compounds for Treating Ocular and Cns Disorders
Application:
11/100,918 →
Use of pde iv inhibitors to treat angiogenesis
Application:
10/527,599 →